Dimethylsiloxane polymers for the effective transdermal delivery of Minoxidil in hair loss treatment.

IF 3.2 4区医学 Q2 ENGINEERING, BIOMEDICAL

Biomedical Engineering Letters Pub Date : 2025-01-29 eCollection Date: 2025-03-01 DOI:10.1007/s13534-025-00460-0

Jaehoon Kim, Dokyoung Kim

{"title":"Dimethylsiloxane polymers for the effective transdermal delivery of Minoxidil in hair loss treatment.","authors":"Jaehoon Kim, Dokyoung Kim","doi":"10.1007/s13534-025-00460-0","DOIUrl":null,"url":null,"abstract":"Purpose: Hair loss affects significant social and psychological well-being issues of the person. Thus, various drugs, ingredients, and technologies are being developed to overcome it. Minoxidil (MXD) is a representative hair loss treatment drug because it suppresses the production of dihydrotestosterone and induces vasodilation. However, since MXD has various side effects when used orally, it is more desirable to use it topically. In this work, we disclosed a new polymeric formulation (MXD@CP) based on citric acid (CA) dimethylsiloxane polymer (CP) for the effective transdermal delivery of MXD.Methods: The polymer that induced ring-opening polymerization based on CA was named CA-siloxane polymer (CP). After CP synthesis, MXD was loaded onto CP to form MXD@CP. The formed MXD@CP was confirmed to have efficacy as a transdermal delivery system through various material property analyses and biotoxicity and therapeutic efficacy analyses.Results: In these results, CP stably loaded MXD up to 5%, a concentration used in clinical practice, and showed higher hair growth efficacy and hair follicle formation efficacy compared to MXD@PBS.Conclusion: In the animal study, MXD@CP showed a superior hair growth effect which suggests its potential as a next-generation hair loss treatment agent.Supplementary information: The online version contains supplementary material available at 10.1007/s13534-025-00460-0.","PeriodicalId":46898,"journal":{"name":"Biomedical Engineering Letters","volume":"15 2","pages":"437-442"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871241/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Engineering Letters","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s13534-025-00460-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Hair loss affects significant social and psychological well-being issues of the person. Thus, various drugs, ingredients, and technologies are being developed to overcome it. Minoxidil (MXD) is a representative hair loss treatment drug because it suppresses the production of dihydrotestosterone and induces vasodilation. However, since MXD has various side effects when used orally, it is more desirable to use it topically. In this work, we disclosed a new polymeric formulation (MXD@CP) based on citric acid (CA) dimethylsiloxane polymer (CP) for the effective transdermal delivery of MXD.

Methods: The polymer that induced ring-opening polymerization based on CA was named CA-siloxane polymer (CP). After CP synthesis, MXD was loaded onto CP to form MXD@CP. The formed MXD@CP was confirmed to have efficacy as a transdermal delivery system through various material property analyses and biotoxicity and therapeutic efficacy analyses.

Results: In these results, CP stably loaded MXD up to 5%, a concentration used in clinical practice, and showed higher hair growth efficacy and hair follicle formation efficacy compared to MXD@PBS.

Conclusion: In the animal study, MXD@CP showed a superior hair growth effect which suggests its potential as a next-generation hair loss treatment agent.

Supplementary information: The online version contains supplementary material available at 10.1007/s13534-025-00460-0.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedical Engineering Letters ENGINEERING, BIOMEDICAL-

CiteScore

6.80

自引率

0.00%

发文量

期刊介绍： Biomedical Engineering Letters (BMEL) aims to present the innovative experimental science and technological development in the biomedical field as well as clinical application of new development. The article must contain original biomedical engineering content, defined as development, theoretical analysis, and evaluation/validation of a new technique. BMEL publishes the following types of papers: original articles, review articles, editorials, and letters to the editor. All the papers are reviewed in single-blind fashion.